Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. - Wikidata - wikimedia - TriplyDB

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

http://www.wikidata.org/entity/Q34157994

about

Anti-vascular endothelial growth factor for diabetic macular oedema Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema Diabetic macular edema: it is more than just VEGF Diabetic Macular Edema Updates on the Clinical Trials in Diabetic Macular Edema Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant The clinical utility of aflibercept for diabetic macular edema Anti-VEGF Therapy and the Retina: An Update Perspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema The role of aflibercept in the management of diabetic macular edema Neuroinflammatory responses in diabetic retinopathy Individualized Treatment of Neovascular Age-Related Macular Degeneration: What are Patients Gaining? Or Losing?Laser, intravitreal drug application, and surgery to treat diabetic eye disease Diabetic retinopathy: variations in patient therapeutic outcomes and pharmacogenomics Receptor tyrosine kinase-mediated angiogenesis Novel pharmacotherapies in diabetic retinopathy A review of therapies for diabetic macular oedema and rationale for combination therapy Spectral-domain optical coherence tomography for macular edema Treatment of diabetic retinopathy: Recent advances and unresolved challenges Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory Administration of Traditional Chinese Blood Circulation Activating Drugs for Microvascular Complications in Patients with Type 2 Diabetes Mellitus Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy Current perspectives on ranibizumab Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema The Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial Cells Standards of medical care in diabetes--2013 Diabetic macular oedema: evidence-based treatment recommendations for Asian countries.Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy.Adipose-derived stem cells from diabetic mice show impaired vascular stabilization in a murine model of diabetic retinopathy.Diabetic macular edema: New promising therapies.CLINICAL EVIDENCE OF THE MULTIFACTORIAL NATURE OF DIABETIC MACULAR EDEMA.Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN study.Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials.Relation between macular morphology and treatment frequency during twelve months with ranibizumab for diabetic macular edema Effect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema.New Therapeutic Approaches in Diabetic Retinopathy.Predictive factors of better outcomes by monotherapy of an antivascular endothelial growth factor drug, ranibizumab, for diabetic macular edema in clinical practice.Cost-effectiveness of treatment of diabetic macular edema.Foveal thickness reduction after anti-vascular endothelial growth factor treatment in chronic diabetic macular edema.Prognostic factors of short-term outcomes of intravitreal ranibizumab in diabetic macular edema.

P2860

Q24193083-C773DE2F-D326-400E-98BE-CEF030956BD0 Q24202071-DCF6189C-1D76-42C8-BFCB-7006F1EB834A Q26745914-BA31137A-E720-4A31-82D7-1EDB1359F5CD Q26749438-AB7F6BC1-AD42-4F72-A762-8A0A3BA96196 Q26767100-B9A1DDA0-4C92-47E0-B8E2-FF0D0E80A960 Q26775853-7C6C4408-05C1-47D7-AFA2-42E9A4B26725 Q26783575-2C36DA42-A07F-45EF-B110-4E9D6A8FDF2E Q26784605-B62AA5DA-7DF9-4326-8407-F0BBF4A375B3 Q26786012-2E79692F-15D5-4856-89BB-42208FCC3170 Q26798348-D75684BB-196A-4F71-A905-3F9A40FF14C2 Q26798351-66ABB230-89E8-458D-812E-7DE52A22BB5F Q26799492-D71062C6-6E85-4262-AF55-99417ADA583B Q26995365-644D8F4B-D75C-4843-98F7-8CADCAAD99A1 Q26998543-13E75DE4-8AD0-4A35-B018-44511D03E461 Q27001612-ED9523FE-FDC6-476F-B648-77D65CA5EDCD Q27002622-C75A059B-F666-4413-B3CA-6A9D5E94FAB5 Q27008325-C5DEE934-B8F5-46F0-A2C4-4DF6141B8B80 Q27016124-810E91BA-2ECB-45BD-AE68-C1BE81E732B2 Q28067491-A376ED48-D73A-49F4-A1B7-DD2D9361648E Q28070894-E8AB54F1-75B6-479F-8732-BB0AC302EC15 Q28072087-861030A2-9BF7-49FE-8920-2C013C90F648 Q28078199-47B140C9-BCB5-42C7-915C-DC934D81DA0A Q28082383-00FCBF93-1507-4BF6-A14F-FDA49FBA7C16 Q28292764-CD735050-88F3-4D6E-A1F1-494F5D6AA507 Q28550616-3D158237-5756-4E8F-A72A-1C55EC7CB936 Q29620309-A0BF9C63-8C4E-4953-B455-CDDE7318E795 Q30101045-B141424C-BF29-4FFE-88F8-14435E0B1DAB Q30244247-26CDE0DB-B0EF-402E-B7C9-8607FDA293B8 Q30300372-1420A500-7C26-45B3-A595-602ABE759622 Q30415630-C76BDC8D-2E75-48E1-9B7F-1CE1210D6DD9 Q30491050-086E3FD0-4404-49BB-BB36-38A6E2F83E61 Q31131691-64BD9606-DA1A-4C8F-AFD7-0E928B8559E1 Q31155420-E2EA8CA1-328C-4C62-A1CF-BC4F4A8D2243 Q33563100-AD3F42CB-CE3A-47FF-8AED-C355B396D043 Q33568545-24CE1353-DE14-4838-AD3C-0CA89DFC0A63 Q33583037-9ADE3E1A-78C5-40E9-B2F0-CAFEAE267370 Q33606076-00392AC3-0C64-48A3-B4D1-E5EE92167A4F Q33606611-ED78903C-AAE9-498F-A4A6-BE1622C62DEC Q33706093-249456B9-E997-48CA-B811-DA7B773BCA44 Q33706098-8E44B273-7C06-4A2C-B2F5-B255AA2E8692

P2860

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

http://www.wikidata.org/entity/Q34157994

description

2012 nî lūn-bûn

@nan

2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Ranibizumab for diabetic macul ...... domized trials: RISE and RIDE.

@ast

Ranibizumab for diabetic macul ...... domized trials: RISE and RIDE.

@en

Ranibizumab for diabetic macul ...... domized trials: RISE and RIDE.

@nl

type

label

Ranibizumab for diabetic macul ...... domized trials: RISE and RIDE.

@ast

Ranibizumab for diabetic macul ...... domized trials: RISE and RIDE.

@en

Ranibizumab for diabetic macul ...... domized trials: RISE and RIDE.

@nl

prefLabel

Ranibizumab for diabetic macul ...... domized trials: RISE and RIDE.

@ast

Ranibizumab for diabetic macul ...... domized trials: RISE and RIDE.

@en

Ranibizumab for diabetic macul ...... domized trials: RISE and RIDE.

@nl

P1433

Q34157994-BD58DE8E-F701-4298-A445-434C3C82EE8A

P1476

Q34157994-2CB7AF44-0372-40EF-9999-D9B7C7E43011

P2093

Q34157994-04C34343-279B-4D97-84A9-E00A405EBED0

Q34157994-0742AB4C-D091-4550-A935-1594C471337E

Q34157994-32950C20-6F8D-4EF9-9B17-FF319BDEF152

Q34157994-3B234B2F-B869-4D31-9C29-1D5A85D3319F

Q34157994-4A1774C1-A72E-4A91-96B3-5FDAB4F0F8A3

Q34157994-5B5BCD55-4EC7-44D5-92EE-7216A58E9E87

Q34157994-654C4429-0D47-4C34-9873-BB7DB25C06AA

Q34157994-9455BF2A-FAF0-407E-87EB-6CE8446ADB8B

Q34157994-9C357E64-6032-4562-9A42-A573F6976F2C

Q34157994-9DFBFF47-AFAE-4E73-B18C-44311B06FB90

P304

Q34157994-4A46B30B-894A-485B-A471-A544DF932F8A

P31

Q34157994-4D3BE070-7271-486F-8633-C330163DA14D

P356

Q34157994-54B8618D-C193-487C-B1C8-579D53BD1361

P433

Q34157994-B4445B6C-086B-4D97-980F-52F0DF83C838

P478

Q34157994-B6428102-7456-49DE-BDA4-A64A16B94453

P577

Q34157994-F7FB3C0B-F46F-4D4C-83C7-E7F384241F1A

P698

Q34157994-BD37E5CC-7797-442B-AC91-C6E00F71BE22

P921

Q34157994-094F993A-A523-4C88-94A3-39257CF1231F

P356

J.OPHTHA.2011.12.039

P1433

P1476

Ranibizumab for diabetic macul ...... domized trials: RISE and RIDE.

@en

P2093

Amy Chen Rundle

http://www.w3.org/2001/XMLSchema#string

Andrea Gibson

http://www.w3.org/2001/XMLSchema#string

David M Brown

http://www.w3.org/2001/XMLSchema#string

David S Boyer

http://www.w3.org/2001/XMLSchema#string

Dennis M Marcus

http://www.w3.org/2001/XMLSchema#string

J Jill Hopkins

http://www.w3.org/2001/XMLSchema#string

Jason S Ehrlich

http://www.w3.org/2001/XMLSchema#string

Judy Sy

http://www.w3.org/2001/XMLSchema#string

Leonard Feiner

http://www.w3.org/2001/XMLSchema#string

Quan Dong Nguyen

http://www.w3.org/2001/XMLSchema#string

P304

789-801

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.OPHTHA.2011.12.039

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22330964

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial